North America Intravenous Immunoglobulin Market Size and Forecasts, Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Application, Distribution Channel, End User, and Country

Description

List of Tables

The North America intravenous immunoglobulin market size was valued at US$ 5.042 Bn in 2022 and is expected to reach US$ 8.747 Bn by 2030; it is estimated to record a CAGR of 7.1% from 2022 to 2030. The North America intravenous immunoglobulin market growth is primarily driven by increase in use of immunoglobulins and rising prevalence of immunodeficiency diseases

New Product Launches and Approvals Opportunity for Growth of Intravenous Immunoglobulin Market

In recent years, there have been various developments in the intravenous immunoglobulin market in North America. Market players have been launching new products and seeking regulatory approvals for their offerings. In April 2023, Takeda Pharmaceutical Company Limited, an R&D-driven biopharmaceutical leader, received a supplemental Biologics License Application (sBLA) approval from the US Food and Drug Administration (FDA) to expand the use of HYQVIA to treat primary immunodeficiencies (PI) in children belonging to the age group of 2-16 years. Only HYQVIA's subcutaneous immune globulin (ScIG) infusion allows for monthly administration. In 2022, Health Canada approved HyQvia, a new Immunoglobulin (IG) treatment for Canadians with immune deficiencies. In February 2021, Pfizer Inc. received an sBLA approval for PANZYGA (10% liquid intravenous immunoglobulin preparation) to treat chronic inflammatory demyelinating polyneuropathy (CIDP)

Type-Based Insights

The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022-2030.

Application-Based Insights

Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022-2030.

Distribution Channel -Based Insights

Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022-2030.

End User - Based Insights

Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022-2030.

Patients with autoimmune diseases are treated with intravenous immunoglobulins. Autoimmune diseases are conditions wherein the immune system accidentally attacks its own tissues or cells. Chronic inflammation, and organ and system damage result from this aberrant immune reaction against healthy cells. Fatigue, joint pain, muscle weakness, skin rashes, and neurological disturbances are a few of the typical signs and symptoms of autoimmune diseases. Symptoms of autoimmune diseases such as Guillain-Barre syndrome (GBS), myasthenia gravis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (LE), and immune thrombocytopenia (ITP) can be alleviated with the IVIG therapy. Benefits of this therapy include the rapid relief of symptoms and long-lasting effects, leading to improved quality of life among patients.

According to the Intermountain Healthcare, autoimmune and immune-mediated diseases and conditions affect 23.5-50 million Americans. According to the Centers for Disease Control and Prevention, rheumatoid arthritis (RA) is the most prevalent type of autoimmune arthritis, and 1 in 4 adults in the US has arthritis. As per the Myasthenia Gravis Foundation of America, Inc., the prevalence of myasthenia gravis (MG) is estimated at 14-20 per 100,000 of the US population. In Canada, the incidence of MG is estimated to be 23 per 1 million person-years, with a prevalence of 263 per 1 million people, and the numbers have been stable over the past few decades.

Increase in Use of Immunoglobulins Bolsters North America Intravenous Immunoglobulins Market

Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is rising with the surging use of these antibodies for treating various conditions.

Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the leading companies operating in the intravenous immunoglobulin market.

A few of the major primary and secondary sources referred to while preparing the report on the North America intravenous immunoglobulin market are the Myasthenia Gravis Foundation of America, Journal of Allergy and Clinical Immunology, Genetic and Rare Diseases Information Center, Immune Deficiency Foundation, GBS Foundation, Centers for Disease Control and Prevention

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America intravenous immunoglobulin market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the North America intravenous immunoglobulin market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Product Code: TIPRE00030117

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Intravenous Immunoglobulin Market, by Geography
2.2 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Intravenous Immunoglobulin Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. Intravenous Immunoglobulin Market - Key Industry Dynamics

5.1 Market Drivers:
- 5.1.1 Increase in Use of Immunoglobulins
- 5.1.2 Rising Immunodeficiency Disease Prevalence
5.2 Market Restraints
- 5.2.1 High Cost of Therapy
5.3 Market Opportunities
- 5.3.1 New Product Launches and Approvals
5.4 Future Trends
- 5.4.1 Strong Pipeline of IVIG Candidates
5.5 Impact Analysis:

6. Intravenous Immunoglobulin Market - North America Market Analysis

6.1 Intravenous Immunoglobulin Market Revenue (US$ Mn), 2022 - 2030

7. North America Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 - by Type

7.1 Overview
7.2 Intravenous Immunoglobulin Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 IgG
- 7.3.1 Overview
- 7.3.2 IgG: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
7.4 IgA
- 7.4.1 Overview
- 7.4.2 IgA: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
7.5 IgM
- 7.5.1 Overview
- 7.5.2 IgM: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 Intravenous Immunoglobulin Market Revenue Share, by Application, 2022 & 2030 (%)
8.3 Immunodeficiency Diseases
- 8.3.1 Overview
- 8.3.2 Immunodeficiency Diseases: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy
- 8.4.1 Overview
- 8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Idiopathic Thrombocytopenic Purpura
- 8.5.1 Overview
- 8.5.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Multifocal Motor Neuropathy
- 8.6.1 Overview
- 8.6.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.7 Hypogammaglobulinemia
- 8.7.1 Overview
- 8.7.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.8 Guillain-Barre Syndrome
- 8.8.1 Overview
- 8.8.2 Guillain-Barre Syndrome: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.9 Specific Antibody Deficiency
- 8.9.1 Overview
- 8.9.2 Specific Antibody Deficiency: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.10 Inflammatory Myopathies
- 8.10.1 Overview
- 8.10.2 Inflammatory Myopathies: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.11 Myasthenia Gravis
- 8.11.1 Overview
- 8.11.2 Myasthenia Gravis: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
8.12 Others
- 8.12.1 Overview
- 8.12.2 Others: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 - by Distribution Channel

9.1 Overview
9.2 Intravenous Immunoglobulin Market Revenue Share, by Route of Administration, 2022 & 2030 (%)
9.3 Hospital Pharmacy
- 9.3.1 Overview
- 9.3.2 Hospital Pharmacy: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Retail Pharmacy
- 9.4.1 Overview
- 9.4.2 Retail Pharmacy: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Others
- 9.5.1 Overview
- 9.5.2 Others: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 - by End User

10.1 Overview
10.2 Intravenous Immunoglobulin Market Revenue Share, by Species, 2022 & 2030 (%)
10.3 Hospitals
- 10.3.1 Overview
- 10.3.2 Hospitals: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Specialty Clinics
- 10.4.1 Overview
- 10.4.2 Specialty Clinics: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)
10.5 Others
- 10.5.1 Overview
- 10.5.2 Others: Intravenous Immunoglobulin Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Intravenous Immunoglobulin Market - Geographical Analysis

11.1 North America Intravenous Immunoglobulin Market, Revenue and Forecast To 2030
- 11.1.1 Overview
- 11.1.2 North America Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.3 North America: Intravenous Immunoglobulin Market, by Type, 2020-2030 (US$ Million)
- 11.1.4 North America: Intravenous Immunoglobulin Market, by Application, 2020-2030 (US$ Million)
- 11.1.5 North America: Intravenous Immunoglobulin Market, by Distribution Channel, 2020-2030 (US$ Million)
- 11.1.6 North America: Intravenous Immunoglobulin Market, by End User, 2020-2030 (US$ Million)
- 11.1.7 North America Intravenous Immunoglobulin Market, by Country
  - 11.1.7.1 US
    - 11.1.7.1.1 Overview
    - 11.1.7.1.2 US Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.7.1.3 US: Intravenous Immunoglobulin Market, by Type, 2020-2030 (US$ Million)
    - 11.1.7.1.4 US: Intravenous Immunoglobulin Market, by Application, 2020-2030 (US$ Million)
    - 11.1.7.1.5 US: Intravenous Immunoglobulin Market, by Distribution Channel, 2020-2030 (US$ Million)
    - 11.1.7.1.6 US: Intravenous Immunoglobulin Market, by End User, 2020-2030 (US$ Million)
  - 11.1.7.2 Canada
    - 11.1.7.2.1 Overview
    - 11.1.7.2.2 Canada Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.7.2.3 Canada: Intravenous Immunoglobulin Market, by Type, 2020-2030 (US$ Million)
    - 11.1.7.2.4 Canada: Intravenous Immunoglobulin Market, by Application, 2020-2030 (US$ Million)
    - 11.1.7.2.5 Canada: Intravenous Immunoglobulin Market, by Distribution Channel, 2020-2030 (US$ Million)
    - 11.1.7.2.6 Canada: Intravenous Immunoglobulin Market, by End User, 2020-2030 (US$ Million)
  - 11.1.7.3 Mexico
    - 11.1.7.3.1 Overview
    - 11.1.7.3.2 Mexico Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.7.3.3 Mexico: Intravenous Immunoglobulin Market, by Type, 2020-2030 (US$ Million)
    - 11.1.7.3.4 Mexico: Intravenous Immunoglobulin Market, by Application, 2020-2030 (US$ Million)
    - 11.1.7.3.5 Mexico: Intravenous Immunoglobulin Market, by Distribution Channel, 2020-2030 (US$ Million)
    - 11.1.7.3.6 Mexico: Intravenous Immunoglobulin Market, by End User, 2020-2030 (US$ Million)

12. North America Intravenous Immunoglobulin Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies in North America Intravenous Immunoglobulin Market
12.3 Inorganic Growth Strategies
- 12.3.1 Overview
12.4 Organic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Takeda Pharmaceutical Co Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Grifols SA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Pfizer Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Octapharma AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Kedrion SpA
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 CSL Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 LFB Group
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms